PVR and glioblastoma: Co-targeting CD155 and CD73 relieves the GBM microenvironment from two major sources of immune resistance: a potent immunosuppressive axis which directly inhibits NK cell function, and metabolic reprogramming of the local TME that directly impacts metabolic fitness.